0001209191-23-009899.txt : 20230215 0001209191-23-009899.hdr.sgml : 20230215 20230215193059 ACCESSION NUMBER: 0001209191-23-009899 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230209 FILED AS OF DATE: 20230215 DATE AS OF CHANGE: 20230215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Delaet Ingrid CENTRAL INDEX KEY: 0001965808 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 23636814 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-02-09 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001965808 Delaet Ingrid 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Regulatory Officer Common Stock 3382 D Incentive Stock Option 106.02 2031-02-01 Common Stock 3359 D Non-Qualified Stock Option 106.02 2031-02-01 Common Stock 9367 D Incentive Stock Option 79.02 2032-01-31 Common Stock 827 D Non-Qualified Stock Option 79.02 2032-01-31 Common Stock 12261 D Restricted Stock Unit Common Stock 4717 D Restricted Stock Unit Common Stock 5435 D Restriced Stock Unit Common Stock 3202 D Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022. Option granted January 31, 2022 and vests monthly over four years. 1/4 of the Restricted Stock Units vested on February 1, 2022 and February 1, 2023. The remaining units vest equally on each of February 1, 2024 and February 1, 2025. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. 1/2 of the Restricted Stock Units vested on August 27, 2022. The remaining units will vest on August 27, 2023. 1/4 of the Restricted Stock Units vested on January 31, 2023. The remaining units vest equally on each of January 31, 2024, January 31, 2025, January 26, 2026. /s/ Darin Lippoldt, Attorney-in-Fact 2023-02-15 EX-24 2 attachment1.htm EX-24 DOCUMENT

LIMITED POWER OF ATTORNEY - SECURITIES LAW COMPLIANCE

The undersigned, as an officer of Neurocrine Biosciences, Inc. (the
"Corporation"), hereby constitutes and appoints, jointly and severally Kevin C.
Gorman, Matt Abernethy, and Darin Lippoldt, each of them, the undersigned's
true and lawful attorney-in-fact and agent, each with the power of substitution
for her in any and all capacities to complete and execute such Forms 144,
advisable pursuant to Rule 144 promulgated under the Securities Act of 1933
(as amended) and Forms 3, 4, and 5 advisable pursuant to section 16 of the
Securities Exchange Act of 1934, and other forms as such attorney shall in his
or her discretion determine to be required by the rules
and regulations promulgated thereunder, or any successor laws and regulations,
as a consequence of the undersigned's ownership, acquisition or disposition of
securities of the Corporation, and to do all acts necessary
in order to file such forms with the Securities and Exchange Commission, any
securities exchange or national association, the Corporation and such other
person or agency as the attorney shall deem appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and
agents shall do or cause to be done by virtue hereof.

This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 144, 3, 4,
and 5 with repect to the undersigned's holdings of and transactions
in securities issued by the company, (b) revocation by the undersigned in a
signed writing delivered to the foregoing attorneys-in-fact or (c) as to any
attorney-in-fact individually, until such attorney-in-fact shall no
longer be employed by the company.

IN WITNESS WHEREOF, the undersigned has caused this Power Of Attorney to be
executed this 10th day of February 2023.

/s/ Ingrid Dalaet